DelveInsight's Persistent Corneal Edema Market Insights report includes a comprehensive understanding of current treatment practices, persistent corneal edema emerging drugs, market share of ...
Findings of post hoc analyses published in JAMA Ophthalmology suggest that preoperative Scheimpflug imaging can help predict corneal edema resolution following Descemet membrane endothelial ...
Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Corneal Edema Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio There is a “wow” effect from refractive ...
Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, ...
MENLO PARK, Calif., Sept. 22, 2020 /PRNewswire/ -- Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for ...
Company also completes Phase 1 epithelial study to evaluate the safety of topical TTHX1114 to reduce the duration and impact of corneal epithelial defects SAN DIEGO--(BUSINESS WIRE)--Trefoil ...
The Food and Drug Administration recently approved a new contact lens for the treatment of corneal edema —an eye condition that causes swelling, fluid build up, blurred vision, haziness and scarring.
Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) is a revolutionary surgical procedure that allows replacement of the diseased endothelium in cases of endothelial corneal dystrophies ...
TEL AVIV, Israel, June 8, 2021 /PRNewswire/ — EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has ...
SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced a series of data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results